A lawsuit was filed by a current investor in NASDAQ:AMGN shares over alleged breaches of fiduciary duties by certain directors of Amgen, Inc. and current long term NASDAQ:AMGN stockholders should contact the Shareholders Foundation at firstname.lastname@example.org
San Diego, CA -- (SBWIRE) -- 04/02/2013 -- An investor in shares of Amgen, Inc. (NASDAQ:AMGN) filed a lawsuit against directors of Amgen, Inc over alleged breaches of fiduciary duties in connection certain statements.
Investors who are current long-term stockholders in shares of Amgen, Inc. (NASDAQ:AMGN), have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.
In December Amgen, Inc agreed to pay $762 million in criminal fines and a civil settlement in connection with allegations that it marketed its anemia drug Aranesp for off-label uses, offered kickbacks to providers to use its products and engaged in false price reporting practices.
Amgen, Inc. reported that its annual Total Revenue rose from over $15.29 billion in 2011 to over $16.63 billion in 2012 and that its respective Net Income increased from over $3.68 billion to over $4.34 billion.
Shares of Amgen, Inc. (NASDAQ:AMGN) closed on April 1, 2013 at $102.31 per share.
Those who are current long-term investors in shares of Amgen, Inc. (NASDAQ:AMGN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego